AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society ("AHS"), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer.  

The data being presented today builds on previously reported primary structure findings by adding functional evidence demonstrating highly similar biological activity between ABP-450 and BOTOX® across multiple orthogonal analytical approaches: genomic sequence alignment, LC-MS peptide mapping, and the LD50 potency assay. LC-MS peptide mapping demonstrated 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins (NTNH, HA70, HA33, and HA17), with no variant peptides observed between ABP-450 and BOTOX®.  In the LD50 potency assay, all ABP-450 lots fell within predefined equivalence criteria established from BOTOX® reference results, reinforcing functional similarity and further strengthening the analytical foundation supporting biosimilarity.

The AHS Annual Scientific Meeting is a leading forum for headache specialists and a central venue for advancing clinical and scientific dialogue in chronic migraine, the largest therapeutic indication for botulinum toxin. BOTOX® is currently the only botulinum toxin therapy approved for the treatment of chronic migraine.